that's what shorts don't want you to know.
shorts are making up stories...their idiots.
no brainer this is CHEAP.
thanks everyone for posting-- at work and taking a break. I am long and will hold until we reach $100 which will be very soon .
Seeking Alpha Market Currents
4/19/13 Canaccord says "the CF corrector discovery platform" has been validated and the "likelihood for trial success and uptake" has increased. Canaccord raises target to $96
jenn mcnary @jennmcnary 10 Apr
@Rybaxx @greblok @np32817 consider it confirmed. was a very positive meeting
Christine McSherry @fundDuchenne 10 Apr
@jennmcnary great FDA meeting earlier this week
Retweeted by jenn mcnary
Seeking Alpha " Muscular Dystrophy Drug Succeeds, Sarepta Buyers Flood In" Article Link
4/11/13 By: Brian L Wilson
Sarepta is now one of the major players in the field, which is one of the reasons it has received so muchattention this year. Although valuable by itself, eteplirsen is also a financial stepping stone that Sarepta will use to leverage its RNA technology in other indications